Social Media Ideas for Fda Approvals

<![CDATA[FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV,...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Fayuvi]]>

<![CDATA[Your Questions Answered: Two FDA Approvals, Six Platform Deals, and a European Warning]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Hibsago]]>

FDA Approvals in Oncology: July-September 2026

During the third quarter of 2026, the U.S. Food and Drug Administration approved cancer treatments that expanded the options for patients with skin, genitourinary, breast, lung, ga...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Zanvastro]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Onswik]]>

<![CDATA[FDA Approves Imaavy for Warm Autoimmune Hemolytic Anemia in Patients Aged 12 and Older]]>

<![CDATA[FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Tecentriq]]>

<![CDATA[FDA Approves Onswik for Adults with Type 2 Diabetes ]]>

<![CDATA[FDA Grants Accelerated Approval to Jemperli for MSI-H/dMMR Locally Advanced Rectal Cancer]]>

<![CDATA[FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults ]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Expanded Indication for Camzyos]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves New Indication for Kerendia]]>

<![CDATA[FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer]]>

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Imaavy for wAIHA]]>

<![CDATA[Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz ]]>

<![CDATA[FDA Approves Welireg Plus Lenvima for Previously Treated Adult Patients With ccRCC]]>

<![CDATA[FDA Approves Expanded Indication for Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy ]]>

<![CDATA[FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B]]>

<![CDATA[What Moments in FDA’s Review Process Should Patients and Providers be Watching Closely?]]>

The Drugs And Devices Have Been On The Market For Years. But FDA-Ordered Studies Still Aren't Done.

TUESDAY, Sept. 22, 2026 — When the U.S. Food and Drug Administration (FDA) was deciding whether to approve the drug Tavneos several years ago to treat a set of rare autoimmune dise...